HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

COMORBIDITY AND POLYPRAGMACY

Download full text PDF
Issue: 
7
Year: 
2017

V. Shishkova, Candidate of Medical Sciences Center for Speech Pathology and Neurorehabilitation, Moscow

The paper considers the pathogenic association between the development of neurological complications in the most common vascular diseases and the strategy for improving the quality of life in patients with comorbid diseases.

Keywords: 
therapy
comorbidity
cardiovascular diseases
cerebrovascular diseases
diabetes mellitus
stroke
Hypotef



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Zabolevaemost' naselenija Rossii v 2007 godu. Statisticheskie materialy / M., 2008.
  2. Feinstein A. Pre-therapeutic classification of co-morbidity in chronic disease // J. Chronic Disease. – 1970; 23 (7): 455–68.
  3. Kraemer H. Statistical issues in assessing comorbidity // Stat. Med. – 1995; 14: 721–3.
  4. Van den Akker M., Buntinx F., Roos S. et al. Comorbidity or multimorbidity: what’s in a name? A review of the literature // Eur. J. Gen. Pract. – 1996; 2 (2): 65–70.
  5. Fortin M., Lapointe L., Hudon C. et al. Multimorbidity and quality of life in primary care: a systematic review // Health Qual Life Outcomes. – 2004; 2: 51.
  6. Boyd C. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for performance // JAMA. – 2005; 294 (6): 716–24.
  7. Caughey G., Vitry A., Cibert A. Prevalence of comorbidity of chronic diseases in Australia // BMC Public Health. – 2008; 8: 221.
  8. Kuharchuk V.V. Arterial'naja gipertonija, narushenija lipidnogo obmena i ateroskleroz. V kn.: Rukovodstvo po arterial'noj gipertonii. Pod red. E.I. Chazova, I.E. Chazovoj / M.: MediaMedika, 2005; 289–99.
  9. Go A., Chertow G., Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N. Engl. J. Med. – 2004; 351: 1296–305.
  10. Muhin N.A. Snizhenie skorosti klubochkovoj fil'tratsii – obschepopuljatsionnyj marker neblagoprijatnogo prognoza // Ter. arh. – 2007; 6: 5–10.
  11. Sarnak M., Levey A., Schoolwerth A. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention // Hypertension. – 2003; 42: 1050–65.
  12. International Diabetes Federation, Diabetes Atlas, 5th ed. International Diabetes Federation, 2011.
  13. Morris N., Wang S., Stevens L et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes // Diabetology. – 2001; 44 (Suppl. 2): 4–21.
  14. Dedov I.I., Shestakova M.V. Saharnyj diabet / M: Meditsinskoe Informatsionnoe Agenstvo, 2005; 677 s.
  15. Shishkova V.N. Osobennosti razvitija nevrologicheskih oslozhnenij u patsientov s metabolicheskim sindromom: vozmozhnost' korrektsii i profilaktiki // Ter. arh. – 2015; 1: 109–14.
  16. Mannino D., Buist A. Global burden of COPD: risk factors, prevalence, and future trends // Lancet. – 2007; 370 (9589): 765–73.
  17. Shishkova V.N. Nejroprotektsija u patsientov s arterial'noj gipertoniej: minimizatsija neblagoprijatnogo prognoza // Ter. arh. – 2014; 8: 113–8.
  18. Har'kov E.I., Davydov E.L., Grinshtejn Ju.I. i dr. Osobennosti farmakoterapii v pozhilom i starcheskom vozraste // Sib. med. zhurn. – 2010; 5: 131–4.
  19. Otdelenov V.A., Novakova A.N., Karasev A.V. i dr. Otsenka chastoty potentsial'no znachimyh mezhlekarstvennyh vzaimodejstvij u bol'nyh s polipragmaziej v mnogoprofil'nom statsionare // Klin. farmakol. i ter. – 2012; 5: 81–5.
  20. Donaldson M., Touger-Decker R. Vitamin and mineral supplements: friend or foe when combined with medications? // J. Am. Dent. Assoc. – 2014; 145 (11): 1153–8.
  21. Klinicheskie rekomendatsii «Diagnostika i lechenie arterial'noj gipertenzii» Rossijskogo meditsinskogo obschestva po arterial'noj gipertonii, 2013.
  22. Shishkova V.N. Nejroprotektsija u patsientov s arterial'noj gipertoniej: minimizatsija neblagoprijatnogo prognoza // Ter. arh. – 2014; 8: 113–8.
  23. Rumjantseva S.A., Stupin V.A., Oganov R.G. i dr. Teorija i praktika lechenija bol'nyh s sosudistoj komorbidnost'ju. Klinicheskoe rukovodstvo / M., SPb: Mezhdunarodnaja izdatel'skaja gruppa «Meditsinskaja kniga», 2013; 360 s.
  24. Shishkova V.N. Kognitivnye narushenija kak universal'nyj klinicheskij sindrom v praktike terapevta // Ter. arh. – 2014; 11: 128–34.
  25. Chukanova E.I. Sovremennye aspekty epidemiologii i lechenija hronicheskoj ishemii mozga na fone arterial'noj gipertenzii (rezul'taty programmy KALIPSO) // Nevrol., nejropsihiat., psihosomat. – 2011; 3 (1): 38–42.
  26. Putilina M.V., Baranova O.A. Rezul'taty mnogotsentrovoj kliniko-epidemiologicheskoj nabljudatel'noj programmy GLOBUS (opredelenie rasprostranennosti golovokruzhenija i otsenka shem terapii na ambulatornom urovne) // Zhurn. nevrol. i psihiat. im. S.S. Korsakova – 2014; 5: 33–8.
  27. Kozlovskij V.I. Primenenie kavintona u bol'nyh arterial'noj gipertenziej // Meditsina. – 2005; 2: 82–6.
  28. Evdokimova A.G., Evdokimov V.V., Kovalenko E.V. i dr. Klinicheskaja effektivnost' antigipertenzivnoj terapii v fiksirovannyh kombinatsijah: fokus na Gipotef // Terapija. – 2016; 6 (10): 58–65.